Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer

Biomarkers

Volumn 15, Issue 6, 2010, Pages 516-522

  An, Xin ^a,b   Ding, Pei Rong ^a,b   Li, Yu Hong ^a,b   Wang, Feng Hua ^a,b   Shi, Yan Xia ^a,b   Wang, Zhi Qiang ^a,b   He, You Jian ^a,b   Xu, Rui Hua ^a,b   Jiang, Wen Qi ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chemotherapy; Gemcitabine; Neutrophil to lymphocyte ratio (NLR); Pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HEMOGLOBIN; LACTATE DEHYDROGENASE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; NEUTROPHIL COUNT; OVERALL SURVIVAL; PANCREAS CANCER; PROGNOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL MARKERS; BLOOD CELL COUNT; DEOXYCYTIDINE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; LYMPHOCYTES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPHILS; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77955862760     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2010.491557     Document Type: Article

References (22)

1. An X, Li YH, Lin XB, Wang FH, Feng F, Xu RH, Jiang WQ, He YJ.(2009). [Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.] Ai Zheng 28: 286-291.
2. Baize N, Abu Shalaa A, Berthier F, Demarquay JF, Bernard JL, Rahili A, Piche T, Huet PM, Tran A, Caroli-Bosc FX. (2005). Gemcitabine combined with oxaliplatin is safe and effective in patients with previously untreated advanced pancreatic adenocarcinoma. Gastroenterol Clin Biol 29:1006-1009
3. Balkwill F, Mantovani A. (2001). Inflammation and cancer: back to Virchow? Lancet 357:539-545
4. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K. (2009). Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 58:15-23.
5. Clark EJ, Connor S, Taylor MA, Madhavan KK, Garden OJ, Parks RW. (2007). Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma. HPB (Oxford) 9:456-460
6. De Braud F, Cascinu S, Gatta G. (2004). Cancer of pancreas. Crit Rev Oncol Hematol 50:147-155
7. Engelken FJ, Bettschart V Rahman MQ, Parks RW, Garden OJ. (2003). Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol 29:368-373
8. Fogar P, Sperti C, Basso D, Sanzari MC, Greco E, Davoli C, Navaglia F, Zambon CF, Pasquali C, Venza E, Pedrazzoli S, Plebani M. (2006). Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 32:22-28
9. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, Prasad KR. (2008a). Preoperative neutrophil-tolymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 32:1757-1762
10. Gomez D, Morris-Stiff G, Toogood GJ, Lodge JP, Prasad KR. (2008b). Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol 97:513-518
11. Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasad KR, Toogood GJ, Lodge JP. (2008). Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol 34:55-60.
12. Heinemann V Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R. (2006). Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24:3946-3952
13. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Kohne CH, Mingrone W, Stemmer SM, Tamas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W. (2007). Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized multicenter phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25:2212-2217 (Pubitemid 46954645)
14. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, Bajetta E, Saletti P, Figer A, Scheithauer W, Herrmann R. (2008). CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 9:132-138
15. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. (2009). Blood neutrophil-tolymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 16:614-622
16. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. (2003). Platelets and granulocytes in particular the neutrophils form important compartments for circulating vascular endothelial growth factor. Angiogenesis 6:283-287
17. Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. (2005). CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 93:740-743
18. Nieto J, Grossbard ML, Kozuch P. (2008). Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist 13:562-576
19. Ong SL, Garcea G, Thomasset SC, Mann CD, Neal CP, Abu Amara M, Dennison A, R, Berry DP. (2008). Surrogate markers of resecta-bility in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma. J Gastrointest Surg 12:1068-1073
20. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA 3rd, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD. (1996). A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7:347-353
21. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. (2009). Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 137:425-428
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer National Cancer Institute of the United States National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216